Literature DB >> 10852775

Pulmonary glutathione levels in acute episodes of Farmer's lung.

J Behr1, B Degenkolb, T Beinert, F Krombach, C Vogelmeier.   

Abstract

Acute episodes of farmer's lung (FL) are associated with activation and migration of neutrophils into the lungs, causing oxidative stress. We conducted a study to evaluate the effect of episodes of FL on antioxidant defense of the lung by glutathione (GSH). A total of 15 patients with symptomatic FL (one female and 14 males, age 42 +/- 1 yr [mean +/- SEM]) underwent a standardized hay exposure test for 1 h and were then monitored through lung function measurements for 6 h, after which bronchoalveolar lavage (BAL) was performed. As a control, 10 asymptomatic farmers (AF) (two males and eight females, age 43 +/- 1 yr) underwent the same diagnostic procedures. At 3 to 6 h after antigen exposure, the lung function of FL patients was significantly impaired (VC: -31 +/- 4%; single-breath diffusing capacity of carbon monoxide [DL(CO)]: -17 +/- 3%; and Pa(O(2)): -14 +/- 2%, all versus baseline, whereas in AF, only minor changes occurred VC: -4 +/- 5%; DL(CO): -9 +/- 3%, and Pa(O(2)): -5 +/- 2%, all versus baseline). The number of neutrophils in bronchoalveolar lavage fluid was increased in FL patients as compared with AF (29 +/- 7 x 10(4)/ml versus 10 +/- 7 x 10(4)/ml, p < 0.05). The concentrations of total and reduced glutathione (GSH(T) and GSH, respectively) in epithelial lining fluid were decreased in FL patients and increased in AF (GSH(T): 292.5 +/- 27.5 microM versus 1, 185.0 +/- 189.9 microM, respectively, p < 0.001; GSH: 256.8 +/- 22.1 microM versus 1,054.5 +/- 172.9 microM, respectively, p < 0.001). These findings suggest that the individual ability to upregulate GSH in the alveolar space in response to an inflammatory stimulus may have implications for the development of symptomatic FL. We conclude that intrapulmonary GSH levels are distinctly different in patients with FL and AF, and that the regulation of GSH may play an important role in the pathogenesis of FL.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10852775     DOI: 10.1164/ajrccm.161.6.9907112

Source DB:  PubMed          Journal:  Am J Respir Crit Care Med        ISSN: 1073-449X            Impact factor:   21.405


  6 in total

Review 1.  Glutathione redox control of asthma: from molecular mechanisms to therapeutic opportunities.

Authors:  Anne M Fitzpatrick; Dean P Jones; Lou Ann S Brown
Journal:  Antioxid Redox Signal       Date:  2012-03-09       Impact factor: 8.401

Review 2.  Nebulization of glutathione and N-Acetylcysteine as an adjuvant therapy for COVID-19 onset.

Authors:  José Fábio Santos Duarte Lana; Anna Vitória Santos Duarte Lana; Quézia Souza Rodrigues; Gabriel Silva Santos; Riya Navani; Annu Navani; Lucas Furtado da Fonseca; Gabriel Ohana Marques Azzini; Thiago Setti; Tomas Mosaner; Claudio Lopes Simplicio; Taís Mazzini Setti
Journal:  Adv Redox Res       Date:  2021-08-08

3.  Analysis of carbonylated proteins in bronchoalveolar lavage of patients with diffuse lung diseases.

Authors:  Elena Bargagli; Francesco Penza; Cecilia Vagaggini; Barbara Magi; Maria Grazia Perari; Paola Rottoli
Journal:  Lung       Date:  2007-05-12       Impact factor: 3.777

4.  Glutathione peroxidase 3 localizes to the epithelial lining fluid and the extracellular matrix in interstitial lung disease.

Authors:  Andrea C Schamberger; Herbert B Schiller; Isis E Fernandez; Martina Sterclova; Katharina Heinzelmann; Elisabeth Hennen; Rudolf Hatz; Jürgen Behr; Martina Vašáková; Matthias Mann; Oliver Eickelberg; Claudia A Staab-Weijnitz
Journal:  Sci Rep       Date:  2016-07-20       Impact factor: 4.379

Review 5.  The Role of Oxidative Stress in Sarcoidosis.

Authors:  Sara Solveig Fois; Sara Canu; Alessandro Giuseppe Fois
Journal:  Int J Mol Sci       Date:  2021-10-28       Impact factor: 5.923

6.  The treatment of pulmonary diseases and respiratory-related conditions with inhaled (nebulized or aerosolized) glutathione.

Authors:  Jonathan Prousky
Journal:  Evid Based Complement Alternat Med       Date:  2008-03       Impact factor: 2.629

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.